InAADR

Drug Information

Drug Name: Flucytosine (2022-85-7)
PubChem ID: 3366
SMILES: C1=NC(=O)NC(=C1F)N
InchiKey: XRECTZIEBJDKEO-UHFFFAOYSA-N
Therapeutic Category: Anti-Infective Agents, Antifungal Agents, Antimetabolites, Noxae

Computed Drug Properties

Molecular Weight (dalton): 129.094
LogP: -0.5088
Ring Count: 1
Hydrogen Bond Acceptor Count: 3
Hydrogen Bond Donor Count: 2
Total Polar Surface Area: 71.77

This panel provides information on interacting drugs and their ADRs along with references

Interacting drug Toxicity Interaction Type Mechanism Reference

This panel provides drug-protein interaction and their ADRs along with references

Toxicity Interacting Protein Mechanism Reference
5-Fluorouracil-Associated Toxicity Dihydropyrimidine dehydrogenase (Q12882) Severe 5-fluorouracil-associated toxicity (including death) [ ADR Type 2 ] Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy
Angina Pectoris Dihydropyrimidine dehydrogenase (Q12882) It is recommended to measure DPD activity prior to 5-FU based chemotherapy@ which might be helpful in avoiding drug-related toxicity by adjusting the dose of 5-FU individually [ ADR Type 1 ] Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients
Coma Dihydropyrimidine dehydrogenase (Q12882) Cancer patients with DPD deficiency are at increased risk for developing severe neurological toxicity secondary to 5-FU chemotherapy@ and that infusional thymidine should be considered as a potential rescue agent against this particular host toxicity. [ ADR Type 2 ] Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
Encephalopathy Dihydropyrimidine dehydrogenase (Q12882) Cancer patients with DPD deficiency are at increased risk for developing severe neurological toxicity secondary to 5-FU chemotherapy@ and that infusional thymidine should be considered as a potential rescue agent against this particular host toxicity. [ ADR Type 2 ] Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
Gastrointestinal Toxicity Dihydropyrimidine dehydrogenase (Q12882) Severe and potentially life-threatening gastrointestinal toxicity@ myelosuppression@ and neurological toxicity [ ADR Type 2 ] Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
Hypertension Dihydropyrimidine dehydrogenase (Q12882) It is recommended to measure DPD activity prior to 5-FU based chemotherapy@ which might be helpful in avoiding drug-related toxicity by adjusting the dose of 5-FU individually [ ADR Type 1 ] Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients
Myelosuppression Dihydropyrimidine dehydrogenase (Q12882) Severe and potentially life-threatening gastrointestinal toxicity@ myelosuppression@ and neurological toxicity [ ADR Type 2 ] Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
Neurological Toxicity Dihydropyrimidine dehydrogenase (Q12882) Severe and potentially life-threatening gastrointestinal toxicity@ myelosuppression@ and neurological toxicity [ ADR Type 2 ] Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency

This panel provides drug-food interactions and their ADRs along with references

Food Toxicity Reference

This panel provides information on metabolites and their ADRs along with references

Metabolite Toxicity Place of Metabolism Mechanism Reference

This panel provides information on drug category

Toxicity Source
Abdominal Pain ADReCS
Acidosis Renal Tubular MetaADEDB
Agranulocytosis ADReCS
Aids-Related Opportunistic Infections MetaADEDB
Allergic Reaction ADReCS
Anaemia ADReCS
Anemia MetaADEDB
Anemia Aplastic MetaADEDB
Anorexia ADReCS
Aplasia ADReCS
Aplastic Anaemia ADReCS
Asthenia ADReCS
Ataxia ADReCS
Atrial Fibrillation MetaADEDB
Azotaemia ADReCS
Azotemia MetaADEDB
Blood Bilirubin Increased ADReCS
Body Temperature Increased ADReCS
Candidiasis MetaADEDB
Cardiac Arrest ADReCS
Cardiotoxicity ADReCS
Chest Pain ADReCS
Colitis ADReCS
Colitis Ulcerative ADReCS
Confusional State ADReCS
Convulsion ADReCS
Crystal Urine ADReCS
Crystalluria ADReCS
Deafness ADReCS
Decreased Appetite ADReCS
Dermatitis ADReCS
Diarrhea MetaADEDB
Diarrhoea ADReCS
Dry Mouth ADReCS
Duodenal Ulcer ADReCS
Dyspnoea ADReCS
Enterocolitis ADReCS
Eosinophilia ADReCS
Fatigue ADReCS
Feeling Abnormal ADReCS
Gastrointestinal Haemorrhage ADReCS
Gastrointestinal Pain ADReCS
Glioblastoma MetaADEDB
Haemoglobin ADReCS
Haemorrhage ADReCS
Hallucination ADReCS
Headache ADReCS
Hearing Impaired ADReCS
Hepatic Enzyme Increased ADReCS
Hepatic Function Abnormal ADReCS
Hepatic Necrosis ADReCS
Hepatitis MetaADEDB
Hypersensitivity ADReCS
Hypoglycaemia ADReCS
Hypokalaemia ADReCS
Hypokalemia MetaADEDB
Hypokinesia MetaADEDB
Jaundice ADReCS
Kidney Calculi MetaADEDB
Kidney Diseases MetaADEDB
Leukopenia ADReCS
Liver Injury ADReCS
Meningitis Cryptococcal MetaADEDB
Muscular Weakness ADReCS
Nausea ADReCS
Necrosis ADReCS
Neuropathy ADReCS
Neuropathy Peripheral ADReCS
Pain ADReCS
Pancytopenia ADReCS
Paraesthesia ADReCS
Parkinsonism ADReCS
Peripheral Sensory Neuropathy ADReCS
Peritonitis MetaADEDB
Photosensitivity Reaction ADReCS
Pruritus ADReCS
Psychotic Disorder ADReCS
Pyrexia ADReCS
Rash ADReCS
Renal Failure ADReCS
Renal Insufficiency MetaADEDB
Respiratory Arrest ADReCS
Sedation ADReCS
Thrombocytopenia ADReCS
Toxic Epidermal Necrolysis ADReCS
Ulcer ADReCS
Urinary Tract Infections MetaADEDB
Urticaria ADReCS
Ventricular Dysfunction ADReCS
Ventricular Dysfunction Left MetaADEDB
Vertigo ADReCS
Vomiting ADReCS

InAADR: Drug-Protein-ADRs database